Bruce Feinberg, DO

Ruben Mesa, MD, leads a discussion on key benchmarks and final thoughts about good-quality care programs for patients with MPNs, including parameters for judging efficacy and safety.

Jamile Shammo, MD, Ruben Mesa, MD, and Michael Reff, RPh, MBA, discuss having pharmacists on MPN care teams and the effect they have on patient compliance.

Michael Reff, RPh, MBA, provides insight on adherence programs for MPNs and discusses why patients may not be adherent to therapies.

Kathy Oubre and Michael Reff, RPh, MBA, address the lack of treatment adherence among patients with MPNs and how to overcome this with a best-practice approach.

Ruben Mesa, MD, shares his thoughts on stem cell transplantation related to progression-free survival in MPNs, and Kathy Oubre highlights the importance of good working relationships.

Jamile Shammo, MD, discusses creating individual treatment plans for MPNs and following patients to have a better understanding of how they will respond to treatment.

Michael Reff, RPh, MBA; Kathy Oubre; and Ruben Mesa, MD, discuss how telehealth, technology, and innovation have increased patient adherence and created touch points with patients with MPNs.

Jamile M. Shammo, MD, comments on telehealth and the impact on patients who have MPNs during the COVID-19 pandemic.

Kathy Oubre and Michael Reff, RPh, MBA, reflect on reactions to new guidelines for managing MPNs and how practices are integrating the new process, while Ruben Mesa, MD, shares his experience.

Ruben Mesa, MD, and Jamile M. Shammo, MD, discuss treatment guidelines, pathways, and pharmacologic treatment options that play a role in the standard of care for MPNs.

Michael Reff, RPh, MBA, and Kathy Oubre explain the internal guiding documents that aid a practice’s decision-making and workflow when treating patients with MPNs.

Ruben Mesa, MD, and Jamile M. Shammo, MD, discuss available treatment options, such as JAK inhibitors, and the goals of treatment for patients with MPNs.

Jamile Shammo, MD, reviews methods for approaching patient treatment of MPNs and how it differs for each patient and symptom.

Kathy Oubre and Michael Reff, RPh, MBA, explain how they built the process and success factors of quality oncology care for MPNs.

Ruben Mesa, MD, discusses presentation and diagnosis of MPNs as well as life expectancies of ET [essential thrombocythemia], PV [polycythemia vera], and MF [myelofibrosis].

Jamile Shammo, MD, reviews the various types of MPNs [myeloproliferative neoplasms] and how they differ from MDS [myelodysplastic syndrome].

The expanding arsenal of targeted and immuno-oncology drugs has unalterably changed the landscape of systemic cancer treatment, but chemotherapy will remain critical for years if not decades to come.

The complex interplay of behavioral economics may result in reimbursement methodology alternatives to the prevailing fee-for-service payment system having less impact on prescribing behavior than has been conjectured.

Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.

Solutions proposed by patient advocates and physicians to control costs provide approaches to valuing new drug/treatments compared with 1 or several prevailing standards of care. Increasingly, however, the debate over cost is transitioning to a debate over value.

Shifting physician revenue from drug sales to cognitive services for mature pathways providers did not affect practice behavior in this payer-sponsored Oncology Medical Home.

Dawn Holcombe's recent article in Journal of Oncology Practice/The American Journal of Managed Care joint issue, entitled Oncology Managed Programs for Payers and Physicians: Evaluating Current Models and Diagnosing Successful Strategies for Payers and Physicians is addressed.